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Background: Accumulating evidences suggest that tumors are driven by a small population of cells, termed
“cancer stem cells” (CSCs), which may be resistant to current therapeutic approaches. In breast carcinoma, the CSCs
have been identified as a CD44+/CD24− cell population. These rare cells are able to grow as non-adherent sphere-like
structures, termed “mammospheres”, which enables their isolation and expansion in culture. To design efficient
strategies for the complete eradication of CSCs, it is important to identify enzymes and proteins that are known as
anti-cancer targets, and differ in their properties from those present in the none CSCs. Here we investigated the
activity and expression of type I and type II DNA topoisomerases (topo I and topo II) in CSCs and their response to
anti-topoisomerase inhibitors.
Methods: MCF7 breast cancer cells, PC3 prostate cancer cells and 4 T1-Luc-Oct3/4pG mouse mammary carcinoma
cells were grown on low-attachment dishes in specific medium and allowed to form spheres. Enrichment of CSC
population was verified by immunostaining, flow cytometry or fluorescent microscopy imaging. Nuclear protein
extracts were prepared and topoisomerases activity and protein levels were determined. Cell viability was examined by
the MTT and Neutral Red assays.
Results: Unlike the adherent MCF7 cell line, topo I activity is decreased and topo II activity is increased in the CSCs.
However, the relative levels of the enzyme proteins were similar in both mammospheres and adherent cells. Topo
I activity in mammospheres is regulated, at least in part, by PARP-1, as observed by the recovery of topo I activity
after treatment with PARP-1 inhibitor 3-Aminobenzamide. Mammosphere-derived cells show reduced sensitivity to
topo I inhibitor, camptothecin, and increased sensitivity to topo II inhibitor etoposide. Intact mammospheres show
increased resistance to both drugs. A combined treatment of intact mammospheres with either CPT and gefitinib,
or etoposide and erlotinib, increased the anti-cancer effect of both drugs.
Conclusions: The data of this study suggest that the understanding of biological behavior of essential enzymes
such as topoisomerases, in CSCs’ progression and early stages of tumor development, is important for developing
new strategies for cancer treatment as well as new therapies for advanced disease.
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Over the past few decades there has been significant pro-
gress in cancer treatment and overall survival. In addition,
a decreased mortality for some of the common epithelial
malignancies, such as breast and prostate cancers, is being
observed, mainly due to early detection and prevention.
However, the survival of patients with metastatic diseases
has not been dramatically changed [1].
In the past few years, accumulating evidence suggest that
most malignancies are generated by a subset of cells,
termed “cancer stem cells” (CSCs), which may be respon-
sible for tumor resistance to current therapeutic ap-
proaches [1,2] and can give rise to new tumors after long
remissions, probably due to their unique properties of lon-
gevity, quiescence, and self-renewal, similar to normal stem
cells [3]. In addition to these properties, cancer stem cells
express active telomerase, activated anti-apoptotic and re-
pair pathways, and increased multi-drug resistance (MDR)
transporters and migration ability, all of which play an im-
portant role in tumor development and progression [1,4].
Evidence for the existence of CSCs were found in
many types of cancer, including brain, pancreatic and
head and neck cancers, in addition to those mentioned
above [2], which led to the question of whether current
anti-cancer treatments target the right cells [1].
For human breast cancer, the population of cells dis-
playing CSC properties was identified and found to ex-
press the CD44+/CD24–\low cell markers. The unique
ability of these cells to grow in suspension and form
sphere-like structures, termed “mammospheres”, allows
their isolation and expansion in vitro [5,6]. This system
has become a tool for understanding the underlying
mechanisms that regulate stem/progenitor cells’, or cancer
stem cells’, essential activities and pathways [2].
From a clinical outlook, the CSC concept has significant
therapeutic implications, as these cells need to be com-
pletely eradicated in order to provide long-term disease-
free survival and prevent tumor recurrence or metastasis.
The common therapeutic approach includes cytotoxic
compounds that can trigger cell death mechanisms in highly
proliferating cancer cells. Quiescent CSCs are thought to
be more resistant to chemotherapy, as they express a slow
turnover rate [4,7]. However, most CSCs appear to evade
cytotoxic therapies or irradiation through active mecha-
nisms, such as ATP-binding cassette (ABC) transporter
proteins overexpression, active DNA repair systems, and
expression of anti-apoptotic factors [4,8].
To design efficient strategies for the complete eradica-
tion of CSCs, it is important to identify enzymes and
proteins that are known as anti-cancer targets, and differ
in their properties from those present in the tumor cell
populations, that are not designated as CSCs.
DNA topoisomerases are essential nuclear enzymes
that work to resolve topological problems that normallyoccur during DNA metabolism. In humans, the family of
DNA topoisomerases consists of 6 enzyme proteins,
which are divided into two major groups – type I- and
type II-topoisomerases. Their involvement in crucial
DNA associated-processes, such as replication, transcrip-
tion and repair, marked them as a target of several anti-
cancer agents which are used today in the treatment of
various malignancies [9,10]. The catalytic activity of topoi-
somerases involves the formation of transient covalent
bridges of enzyme-DNA complexes. At the interface of
these complex, topoisomerase I interacts with camp-
tothecin (CPT), and several of its analogs (i.e. topote-
can, irinotecan), and topo II interacts with etoposide, to
induce cell-death [11-13].
In previous studies we and others have demonstrated
the increased anti-cancer effect of topoisomerase inhibi-
tors in combination with other anti-cancer agents, such
as tyrosine kinase inhibitors [14-17].
In this study we investigate the activity of topoisome-
rases in cancer stem cells (CSCs) at early stages of tumor
development, and evaluate their sensitivity to topoisome-
rases inhibitors, alone and in combination with tyrosine
kinase inhibitors. Here we show, for the first time, that
topoisomerases are differentially regulated in mammo-
spheres, compared with the parental adherent cells, and
that these alterations in enzymatic activity modulate the
sensitivity of cells to anti-cancer treatments.
Understanding the biological behavior of essential en-
zymes in CSCs, as well as the evaluation of their sensitivity
to clinically used anti-cancer drugs, might lead to better,
more effective treatment protocols.
Methods
Cells
MCF7 human breast cancer cell line was kindly re-
ceived from Prof. Etta Livneh, Ben-Gurion University,
Beer Sheva, Israel. 4 T1-Luc-Oct3/4pG mouse mam-
mary cancer cell line was kindly received from Dr. Zvi
Granot, Hebrew University, Jerusalem, Israel. These cells were
cultured as monolayer in DMEM medium (Beit HaEmek
Biological Industries, Israel). PC3-human prostate cancer
cell line was kindly received from Prof. Shraga Segal,
Ben-Gurion University, Beer Sheva, Israel, and cultured as
monolayer in RPMI 1640 medium (Beit HaEmek Biological
Industries, Israel). Media were supplemented with 10% fetal
bovine serum, 100 units/ml penicillin, 100 μg/ml strepto-
mycin, and 0.29 mg/ml L-glutamine (Beit HaEmek Biological
Industries, Israel). Cell lines were grown in a humidified
incubator supplemented with 5% CO2, at 37°C.
In vitro isolation and expansion of stem-like cancer cells
MCF7 and 4 T1-Luc-Oct3/4pG cells were cultured as sin-
gle cells on non-adherent plates, at a density of 20,000
cells\ml, in the presence or absence of fetal bovine serum,
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grown without serum were cultured in DMEM:F12 medium
solution mix, supplemented with 0.4% bovine serum albu-
min (BSA), 20 ng/ml EGF (Sigma-Aldrich, Israel), 10 ng/ml
bFGF (Beit HaEmek Biological Industries, Israel), and
5 μg/ml insulin (Sigma-Aldrich, Israel). Mammospheres
were collected after 7–10 days in culture. PC3 cells were
cultured as prostaspheres in the same manner, except that
a RPMI:F12 medium solution mix was used, and 20 ng/ml
bFGF were added.
Antibodies and compounds
Supercoiled DNA plasmid pUC19 was purchased from
Fermentas (Hanover, MD, USA). Kinetoplast DNA was
purchased from TopoGen, USA. Erlotinib (Tarceva®) was
kindly provided by Roche Diagnostics GmbH Pharma
Research, Penzberg, Germany. Gefitinib (Iressa™) was
kindly provided by AstraZeneca Pharmaceuticals (Cheshire,
UK). Stock solutions of erlotinib and camptothecin (Sigma,
Israel), at 20 mM, and of gefitinib, at 50 mM, were dis-
solved in DMSO (Sigma-Aldrich, Israel), stored in aliquots
at −80°C and diluted in DMSO before being added to the
reaction mixture or to the cell culture medium. Stock so-
lution of etoposide (Teva, Israel), at 34 mM, was stored at
room temperature.
The primary antisera were as follows: mouse monoclonal
anti-β-actin antibody (MP Biomedicals LLC, USA); rabbit
monoclonal anti-CD44 antibody (Epitomics Inc., USA);
rabbit polyclonal anti-CD133 antibody (Abcam, USA);
mouse anti-γH2AX antibody (Abcam, USA); goat poly-
clonal anti-Lamin B (Santa Cruz Biotechnology Inc., USA);
goat polyclonal (C-15) anti-topo I (Santa Cruz Biotechnol-
ogy Inc., USA); goat polyclonal anti-Topo IIα (Santa Cruz
Biotechnology Inc., USA); mouse monoclonal anti-CD24
antibody was kindly provided by Prof. Mina Fogel, Kaplan
medical center, Israel. Appropriate horseradish peroxidase
secondary antibodies were purchased from Santa Cruz
Biotechnology Inc. Enhanced chemiluminescence (ECL)
reagents were purchased from Biological Industries Beith
Haemek, Israel. Appropriate fluorescent secondary anti-
bodies were purchased from Jackson Immunoresearch la-
boratories Inc., USA. DAPI (4′,6-diamidino-2-phenylindole)
was purchased from Sigma-Aldrich, Israel.
Determination of cellular markers by Immnocytostaining
Adherent MCF7 cells or mammosphere-derived cells were
seeded onto Lab-Tek™ glass chamber slides (Thermo
Scientific, USA) and allowed to adhere overnight. Cells
were fixed with methanol:acetone for 10 min and then
washed with PBS. After blocking with BSA for 30 min,
primary antibody was added and cells were stored
overnight at 4°C. Cells were then washed and the cor-
responding secondary antibody was added for 1 h, in
the dark, at 4°C. DAPI was added, after which cellswere washed, chambers were detached from the slide,
and cells were mounted and covered. Images were ob-
tained by confocal microscopy.
Determination of cellular marker by flow cytometry
Adherent MCF7 cells and mammospheres were collected
and dissociated enzymatically and mechanically. Cells
were washed with PBS and blocked for 30 min with 1%
BSA, in PBS, on ice. Cells were then centrifuged at
1200 rpm and supernatant was discarded. Extracellular
staining was performed by adding a mouse-anti CD24
antibody (courtesy of Prof. Mina Fogel, Kaplan Medical
Center, Israel) to the corresponding samples and stored
on ice. Then, cells were fixed with 1% formaldehyde for
10 min at room temperature. Samples were washed with
1% BSA, in PBS, and cell membrane was permeabilized by
adding 0.1% Triton for 10 min, at room temperature.
Intracellular staining was performed by adding rabbit anti-
CD44 (Epitomics, USA) to the corresponding samples and
stored on ice. Samples were washed and corresponding
secondary antibodies – FITC conjugated anti-mouse IgG
(Jackson Immunoresearch Laboratories, Inc.) and Alexa-
Fluor 633-conjugated anti-rabbit IgG (Life Technologies) –
were used, according to the manufacturer’s instructions
and stored for 30 min on ice, in the dark. Samples were
washed and resuspended in PBS, after which they were ana-
lyzed by flow cytometry.
Cell viability assay
Mammospheres were dissociated to single cells by incu-
bation for 3 minutes with trypsin-EDTA solution (Beit
HaEmek Biological Industries, Israel), at 37°C, and then
suspension with complete medium by repeated pipet-
ting. Cells were centrifuged at 1200 rpm for 5 min, and
trypsin-containing medium was discarded. Cells were re-
suspended with the appropriate medium, plated as tripli-
cates in 96-well plates, at a density of 5,000 cells/well,
and allowed to adhere overnight. Various concentrations
of drugs were added. Control cultures received medium
containing the highest concentration of the vehicle
(DMSO) present in any treatment group. Plates were in-
cubated at 37°C. Cell cytotoxicity was measured by the
Neutral Red viability assay [18] or by the MTT viability
assay (Alfa Aesar, USA). The cytotoxicity values of each
treatment were calculated.
Nuclear protein extracts preparation
Nuclear extracts for topoisomerase assays and Western
blot analysis were prepared as described before [19,20],
except that a mixture of protease inhibitors (final concen-
trations: 2 μg/ml aprotinin, 2 μg/ml leupeptin, 1 μg/ml pep-
statin A, 2 μg/ml antipain, 100 μg/ml PMSF) was added to
the extraction buffers. Total protein concentration was de-
termined by the BIO-Rad protein assay kit.
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Equal quantities of purified calf thymus topo I or nuclear
proteins from drug-treated and untreated cell lines were
added to a topo I specific reaction mixture containing,
at a final volume of 25 μl: 20 mM Tris–HCl (pH 8.0),
1 mM dithiothreitol, 20 mM KCl, 10 mM MgCl2, 1 mM
EDTA, 30 μg/ml bovine serum albumin and 300 ng
pUC19 supercoiled DNA plasmid. The indicated drugs,
at various concentrations, were added to the reaction
mixture prior to addition of the enzyme. Following incu-
bation at 37°C for 30 min, the reaction was terminated
by adding 5 μl of stopping buffer (final concentration:
1% sodium dodecyl sulfate (SDS), 15% glycerol, 0.5%
Bromophenol blue, and 50 mM EDTA pH 8). The reac-
tion products were analyzed by electrophoresis on 1%
agarose gel using a TBE buffer (89 mM Tris–HCl,
89 mM boric acid, and 62 mM EDTA) at 1 V/cm, stained
by ethidium bromide (0.5 μg/ml), and photographed using a
short wavelength UV lamp (ChemiImager™ 5500 equipment,
Alpha Inotech Corporation, CA, USA). Densitometric
analysis of the results was performed using the EZQuant-
Gel software and the percentage of topo I activity was
calculated.
Topoisomerase II activity assay
Equal quantities of purified topo II or nuclear proteins
from drug-treated and untreated cell lines were added to
a topo II specific reaction mixture containing, at a final
volume of 25 μl: 50 mM Tris–HCl (pH 8), 0.5 mM di-
thiothreitol, 85 mM KCl, 10 mM MgCl2, 0.5 mM EDTA,
30 μg/ml BSA, and 300 ng pUC19 supercoiled DNA
plasmid (for purified topo II enzyme) or 80 ng kineto-
plast DNA (for nuclear-derived topo II). The indicated
drugs, at various concentrations, were added to the reac-
tion mixture prior to addition of the enzyme. Following
incubation at 37°C for 30 min, the reaction was termi-
nated by adding 5 μl of stopping buffer (final concentra-
tion; 1% sodium dodecyl sulfate (SDS), 15% glycerol,
0.5% Bromophenol blue, and 50 mM EDTA pH 8). The
reaction products were analyzed by electrophoresis on
1% agarose gel using a TBE buffer (89 mM Tris–HCl,
89 mM boric acid, and 62 mM EDTA) at 1 V/cm, stained
by ethidium bromide (0.5 μg/ml), and photographed using
a short wavelength UV lamp (Chemilmager™ 5500
equipment, Alpha Inotech Corporation, CA, USA).
Densitometric analysis of the results was performed
using the EZQuant-Gel software and the percentage of
topo II activity was calculated.
Determination of the level of cellular proteins by western
blot analysis
Equal quantities of nuclear proteins derived from ad-
herent MCF7 cells or mammospheres were analyzed by
Western blot analysis, as previously described [19,21],using protein-specific antibodies. The immunocomplexes
were detected by enhanced chemiluminescence (ECL).
Results
Isolation and characterization of MCF7-derived cancer
stem-like cells
The isolation of cancer stem cells from tumor cells popu-
lation is based on their ability to grow as spheres in non-
adherent, serum-free conditions. To isolate CSC from the
MCF7 cell line, adherent cells were collected and grown
on low-attachment plates, in a serum-free medium con-
taining EGF, bFGF, and insulin (designated “GFs-derived
mammospheres”). To verify the enrichment of cancer
stem-like population within the spheres, mammospheres
were grown for 7 days, collected and dissociated to single
cells using trypsin-EDTA. Cells were examined for the
CD44high/CD24low breast stem cell phenotype by immu-
nostaining or flow cytometry. The results depicted in
Figure 1A show that indeed, compared to the adherent
parental MCF7 cells, the CSC population is increased in
mammospheres. Flow cytometry measurement revealed
that the adherent MCF7 cells contain 6.2 ± 5.3% of the
CSC population, and the mammospheres display a three-
fold enrichment to a level of 21.5 ± 2.2%.
Although CSCs have been shown to differentiate in
the presence of serum [22,23], we determined whether
MCF7-derived CSCs might also grow as spheres in the
presence of serum (designated “FCS-derived mammo-
spheres”). Indeed, mammospheres were formed in the
presence of 10% fetal calf serum (FCS), and retained this
ability for several passages (Additional file 1). The en-
richment in the aforementioned stem cells markers was
determined by immunostaining and flow cytometry. The
immunostaining results (Figure 1B, C) demonstrate that
the adherent MCF7 cells contain 7.6 ± 0.4% of the CSC
population, while mammospheres display a two-fold
enrichment of CSC markers (p < 0.05), to a level of
16.4 ± 2.4%. Similarly, flow cytometry revealed that
while adherent MCF7 cells contain 6.2 ± 5.3% of the
CSC population, FCS-derived mammospheres display
more than two-fold enrichment of CSCs, to a level of
15.4 ± 5.4% (Figure 1A).
Topo I activity is decreased and Topoisomerase II activity
is increased in MCF7-derived mammospheres
Topoisomerases activity and expression were investigated
in the CSCs-enriched mammospheres and compared to
the parental adherent MCF7 cells. Mammospheres were
collected and nuclear extracts were prepared. Equal pro-
tein quantities were added into a specific reaction mixture
and topo I DNA relaxation activity was examined. The re-
sults depicted in Figure 2A, B show a significant decrease
(p < 0.00001) in mammosphere-topo I activity, compared
to the adherent control. Both FCS- and GFs-derived
Figure 1 CD44High/CD24Low breast stem cell marker-expressing cell population is enriched in mammospheres. MCF7-derived mammospheres
were collected after 7 days in culture and dissociated. Adherent MCF7 and mammosphere-derived cells were stained for CD44 and CD24 breast stem
cell markers and analyzed by flow cytometry (A) and immunostaining (B) for the CD44high/CD24low cell population. (C) Immunofluorescence depiction
of CD44high/CD24low cell population was calculated manually, after acquiring several images from each cell type and counting the number of
cells expressing the appropriate markers, compared to the total cell number. Results for flow cytometry represent means ± SE of 2 different
mammosphere cultures. Results for immunostaining represent means ± SE of 3 different mammosphere cultures. Statistical significance was
determined by the student’s t-test analysis: *p < 0.05.
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ity is reduced by 49 ± 2.4% in FCS-derived mammospheres
and by 47.8 ± 2.8% in GFs-derived mammospheres, com-
pared to the adherent cells.
It has been previously shown that topo II can compen-
sate for topo I deficiency [24]. The decrease in topo I ac-
tivity in MCF7-derived mammospheres, in comparison
with the adherent cell line, led us to examine the activity
of topo II in these cells. Mammospheres were collected
and nuclear protein extracts were made. The parental
adherent MCF7 cells served as controls. Equal proteins
quantities were added to specific reaction mixtures and
topo II decatenation activity was examined. The results
depicted in Figure 2C, D show that topo II activity is sig-
nificantly increased (p < 0.01) in both FCS- and GFs-
derived mammospheres. Topo II activity is elevated by
additional 73.7 ± 14.2% in FCS-derived mammospheres
and by 65.2 ± 13.6% in GFs-derived mammospheres, com-
pared to the adherent MCF7 cells.The relative levels of topoisomerase proteins are not
altered in mammospheres
The changes in the activity of topoisomerases in mammo-
spheres could be the result of (1) a change in the level of
the enzyme protein or (2) posttranslational modifications
that lead to modulation in activity.To address the first possibility, topo I protein level
was examined in nuclear extract proteins derived from
adherent MCF7 cells and mammospheres, using equal
protein quantities. As observed in Figure 3, topo I pro-
tein level was significantly decreased (p < 0.01) in both
FCS- and GFs-derived mammospheres (by 30.1 ± 6.8%
and 35.2 ± 5.8%, respectively), compared to the adherent
MCF7 cells. When we examined the level of β-actin,
which served as a loading control, we noticed a similar re-
duction (p < 0.01) in the protein level (33.5 ± 8.2% and
34.3 ± 6%, respectively).
In order to overcome this problem, we investigated the
level of lamin B, which is abundant nuclear protein that
can serve as a loading control; however a similar decrease
(p < 0.01) was observed (34.2 ± 2.2% and 29 ± 4.8% re-
duction in FCS- and GFs-derived mammospheres,
respectively).
Examination of topo II protein level revealed, again, a
similar pattern (p < 0.05) of protein level reduction (30 ±
17.2% and 33.4 ± 13.3% in FCS- and GFs-derived mam-
mospheres, respectively), despite the increased activity of
the enzyme observed in mammospheres. The overall re-
duction in the level of nuclear proteins, which were ex-
amined in this study, could explain the reduction in
topo I activity in mammospheres; however, it could not
account for the elevated topo II activity in these cells.
Indeed, when we examined the ratio of these proteins to
Figure 2 Topoisomerases activity in mammospheres. MCF7-derived mammospheres were isolated and nuclear extracts were made. Equal
quantities of total nuclear proteins were added to a topo I- or topo II-specific reaction mixture and reaction products were analyzed by agarose
gel electrophoresis. (A) Representative result of topo I DNA-relaxation activity. (B) Quantification analysis of topo I activity. (C) Representative
result of topo II decatenation activity. (D) Quantification analysis of topo II activity. Results represent means ± SE of 3 experiments. Statistical
significance was determined by the student’s t-test analysis: *p < 0.00001; **p < 0.05, compared to the adherent control.
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levels of proteins. Since equal amount of proteins (from
all the examined samples) was added to the enzyme reac-
tion, one may suggest that the modifications in topoisome-
rases activity might be the consequence of posttranslational
modification of the enzyme protein.Figure 3 Level of nuclear proteins in mammospheres. MCF7-derived mam
protein quantities were examined by Western blot analysis for topo I, topo II, β-
using the EZQuant-Gel software and the percentage of nuclear proteins level w
represent means ± SE values of at least 3 experiments. Statistical significance waTopo I activity in mammospheres is regulated by
poly-ADP-ribosylation
Topo I activity is regulated by a number of posttranslational
modifications [24]. One of these modifications, known to
reduce topo I activity, is poly-ADP-ribosylation by the
enzyme poly-ADP-ribose polymerase (PARP). To examinemospheres were isolated and nuclear protein extracts were prepared. Equal
actin, and lamin B (A). Densitometric analysis of the results was performed
as calculated relative to the adherent MCF7 (B) or to β-actin (C). Results
s determined by the student’s t-test analysis: *p< 0.05; **p< 0.01.
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MCF7-derived mammospheres, we used PARP inhibitor,
3-aminobenzamide (3AB). First, the cytotoxicity of various
doses (3–0.01 mM) of 3AB was examined in MCF7
cells, for up to 72 h (not shown). A slight cytotoxic ef-
fect (14.7 ± 4.8%; p < 0.05) was observed at 3 mM after
72 h. Since 3AB did not show marked cytotoxic effect,
adherent MCF7 cells and mammospheres were treated
with 3 mM of 3AB for 24 hours, and topo I activity was
examined using the appropriate nuclear extracts. The
results depicted in Figure 4 show that, indeed, the cellular
topo I activity is increased in mammospheres after PARP
inhibition (from 42 ± 2.5% to 67.4 ± 8.3%), and restored to
a comparable level as observed in adherent MCF7 cells
after 3AB treatment (67.6 ± 2.6%). These results indicate
that topo I activity in mammospheres is regulated, at least
in part, by poly-ADP-ribosylation.Reduction of topo I activity is a common characteristic of
stem cell sphere-formation
To further substantiate the changes in topo I activity ob-
served in mammospheres, we utilized other cancer stem
cell systems. Adherent 4 T1-Luc mouse mammary carcin-
oma cells, transfected with Oct3/4 pGreenZeo promoter
reporter construct (express green fluorescent protein
zsGreen under the stem cell marker Oct-3/4 promoter),
were grown as mammospheres, as mentioned before. Cells
were examined for Oct-3/4 expression by the visualization
of fluorescence, under the same exposure setting. Figure 5A
demonstrates increased expression of Oct3/4 stem cell
marker (green) in mammospheres, compared to the
parental adherent 4 T1-Luc-Oct3/4pG cells, indicating an
enrichment of cancer cells with stem-like properties.
After the establishment of mammospheres’ stem-like
properties, adherent 4 T1-Luc-Oct3/4pG cells and their
derived mammospheres were collected, nuclear protein
extracts were prepared, and topo I activity was exam-
ined. The results depicted in Figure 5B and C show that
in mouse mammary CSCs, similarly to human cells, topoFigure 4 Effect of 3-aminobenzamide on cellular topo I activity in ma
were plated at a density of 106 cells\plate and treated with 3 mM 3-aminob
I activity was examined (A). Topo I activity was quantified and plotted (B).
was determined by the student’s t-test analysis: *p < 0.05; **p < 0.01.I activity is reduced (p < 0.05) by 47.5 ± 8.5%, compared
to the parental adherent cell line.
Furthermore, we utilized the sphere formation assay to
isolate prostate CSCs from the human PC3 cell line, in
both FCS- and GFs-supplemented media. PC3-derived
spheres (termed “prostaspheres”) were collected and ex-
amined for expression of stem cell marker CD133 by im-
munostaining. The results depicted in Figure 6A show
that prostaspheres express higher levels of CD133 than the
parental adherent cells, indicating stem cell enrichment.
After the establishment of stem-like properties, prosta-
spheres were collected and nuclear protein extracts were
prepared. Topo I activity was examined and compared
to the parental adherent PC3 cells. The results depicted
in Figure 6B and C show that in accordance with the
aforementioned observations, compared to the parental
adherent cells, prostaspheres exhibit decreased topo I ac-
tivity (p < 0.01), as FCS-derived spheres show a 62 ± 8.4%
decrease and GFs-derived spheres show a 76.3 ± 8.3%
decrease.
The regulation of stem cell self-renewal and differenti-
ation has been shown to induce chromatin remodeling
processes. It has been demonstrated that mouse embry-
onic stem cells (mESCs) and mouse iPS cells have high
basal levels of γH2AX, in a mechanism that is not
dependent on DNA damage response. Levels of γH2AX
have been shown to decrease upon differentiation, and in-
crease in the presence of self-renewal-enhancing mole-
cules [25]. Here we examined γH2AX levels in MCF7-
derived mammospheres by the immunostaining assay.
The results depicted in Figure 7 show that γH2AX levels
(red) are elevated in mammosphere-derived cells, com-
pared to the adherent MCF7 cells, suggesting self-renewal
regulation processes.
Mammosphere-derived cells are resistant to topo I
inhibition by CPT or TPT and sensitive to topo II
inhibition by etoposide
Since CPT (and its derivatives) and etoposide exert their
inhibitory effect on DNA-bound topoisomerases, i.e., activemmospheres after 24 h. Adherent MCF7 cells and mammospheres
enzamide (3AB) for 24 hours. Nuclear extracts were prepared and topo
Results represent means ± SE of 3 experiments. Statistical significance
Figure 5 Topo I activity in 4 T1-Luc-Oct3/4pG-derived mammospheres. Adherent 4 T1-Luc mouse cells, expressing green fluorescent protein
zsGreen under Oct-3/4 promoter, were grown as mammospheres under the conditions indicated. (A) Mammospheres were examined for Oct-3/4
expression by the visualization of fluorescence (green) under the same exposure setting expression. Images were obtained by fluorescent microscopy.
After 6 days in culture, 4 T1-Luc-Oct3/4pG-derived mammospheres were isolated and nuclear extracts were made. Total nuclear proteins were added to
a topo I-specific reaction mixture and reaction products were analyzed by agarose gel electrophoresis. (B) Representative result of topo I DNA-relaxation
activity. (C) Quantification analysis of topo I activity. Results represent means ± SE of 3 experiments. Statistical significance was determined by
the student’s t-test analysis: *p < 0.05.
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mammospheres, is expected to result in the reduction of
total DNA bound-topo I, rendering reduced sensitivity to
CPT and its derivatives. Similarly, elevated topoII activity,
as observed for mammospheres, is expected to result in
the increase of total DNA bound-topo II, rendering in-
creased sensitivity to etoposide. Therefore, MCF7 cells
were grown as mammospheres for 7 days and then dis-
sociated enzymatically, using trypsin-EDTA. Cells were
seeded as triplicates in a 96-well plate at a density of
5,000 cells/well, in the presence of 1% serum, to allow
proper attachment. Cells were treated with CPT, topote-
can (also termed TPT – a CPT derivative currently in
use as an anti-cancer drug [9]), and etoposide for
24 hours; cell viability was measured by the Neutral red
cytotoxicity assay.
The results depicted in Figure 8A show that the ad-
herent MCF7 cells are significantly more resistant to
etoposide treatment, compared to cells derived from
mammospheres. Etoposide, at 100 μM, reduced the viabil-
ity of adherent cells by 33.1 ± 7.7%, while the reduction of
cell viability in mammosphere-derived cells was 63.5 ±
9.3% in FCS-derived mammospheres and 74.7 ± 1.7% in
GFs-derived mammospheres (p < 0.05). It is notable that
the adherent cells showed remarkable recovery at doses
lower than 100 μM, whereas the mammosphere-derived
cells did not. While MCF7 cells showed complete resistanceto 50 μM of etoposide, significant decrease in cell viability
(p < 0.05) of 14.2 ± 8.2% was observed for FCS-derived
mammosphere cells and 20.5 ± 10.7% for GFs-derived
mammosphere cells.
In contrast, the adherent MCF7 cells showed signifi-
cantly higher sensitivity to CPT treatment, compared to
cells derived from mammospheres (p < 0.05). The results
depicted in Figure 8B show that CPT, at 5 μM to 1 μM,
caused 46.9% to 34.8 ± 1.5% reduction (respectively) in the
viability of the adherent cells, while in the FCS-derived
mammosphere cells CPT treatment showed 35.4 ± 0.7% to
19.8 ± 1.2% decrease in cell viability (a 23.3–11.6% differ-
ence), and in the GFs-derived mammospheres it exhibited
a 23.6 ± 2.4% to 23.2 ± 0.8% decrease in cell viability
(22–8% difference).
In addition to CPT, we examined the sensitivity of the
cells to another topo I inhibitor – topotecan (TPT), a
water soluble derivative of CPT. As depicted in Figure 8C,
significant resistance was observed with TPT treatment in
mammosphere-derived cells, compared to the adherent
cells (p < 0.05). TPT, at 10 μM to 5 μM, respectively,
caused 45.8 ± 0.32% to 37.7 ± 0.56% reduction in the via-
bility of adherent cells, while FCS-derived mammosphere
cells showed32.9 ± 0.4% to 27.5 ± 0.7% reduction in cell
viability (12.9–10.2% difference), and GFs-derived mam-
mospheres showed 21.7 ± 2.1% to 20.8 ± 2.2% (24.1–16.9%
difference) reduction in cell viability.
Figure 6 Topo I activity in PC3-derived prostaspheres. PC3-derived spheres were collected and dissociated enzymatically to single cells.
(A) Adherent PC3 and prostasphere-derived cells were stained for CD133 stem cell marker and analyzed by immunostaining. Results represent 3
different prostasphere cultures. PC3-derived prostaspheres were isolated and nuclear extracts were made. Equal quantities of total nuclear proteins
(25 ng) were added to a topo I-specific reaction mixture and reaction products were analyzed by agarose gel electrophoresis. (B) Representative
result of topo I DNA-relaxation activity. (C) Quantification analysis of topo I activity. Results represent means ± SE of 3 experiments. Statistical
significance was determined by the student’s t-test analysis: **p < 0.01, compared to the adherent control.
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to topoisomerases inhibition, by both CPT and etoposide,
compared to the adherent MCF7 cells
In the above described experiments, the sensitivity of cell
suspensions derived from mammospheres to topoisomer-
ase inhibitors was determined. However, since the struc-
ture of a mammosphere may interfere with the entrance
of the drugs, we investigated the sensitivity of the intact
mammospheres to topoisomerase antagonists alone, as a
single drug, or in combination with other anti-cancer
drugs. Mammospheres were grown for 5–7 days, col-
lected, and total number of cells was evaluated. Mammo-
spheres were seeded in low-attachment 96-well plates and
treated with various combinations of the indicated drugs
for up to 48 hours. Cell viability was examined every
24 hours by the MTT viability assay. The results depicted
in Figure 9 show that, as expected, CPT exhibits reduced
cytotoxicity in mammospheres compared to the adherent
cells (A, B). However, unexpectedly, etoposide also
showed significant (p < 0.05) reduced cytotoxicity in mam-
mospheres (C, D). This was not compatible with the ele-
vated topo II activity (see Figure 2), and the sensitivity of
mammosphere-derived cells (see Figure 8).To examine the possibility that this reduced sensitivity
is affected by the inability of MTT to enter the bulk of
cells in mammospheres, rather than the cytotoxic effects
of the indicated topoisomerase inhibitors, intact and dis-
sociated mammospheres were grown on 96-well plates,
without treatment. After 24 hours in culture, cell viabil-
ity was examined by either MTT (for intact spheres) or
Neutral red (for dissociated single cells, grown as mono-
layer) assays. As depicted in Figure 10, cell viability was
not significantly different for both dissociated and intact
mammospheres, suggesting that the cellular structure
does not influence the indicated viability assay, and that
these assessments are appropriate. Thus, the differed
sensitivities for CPT and etoposide shown in Figures 8
and 9, probably stem from active cellular mechanisms,
obtained by the sphere formation process.
A combined treatment of CPT with Gefitinib or etoposide
with Erlotinib shows increased cytotoxic effect in
mammospheres
Previous studies have demonstrated an increased anti-
cancer effect of the combination of topoisomerase in-
hibitors and tyrosine kinase antagonists [14-17]. The
Figure 7 Levels of γH2AX in adherent MCF7 cells and mammospheres. Adherent MCF7 cells (A) and mammosphere-derived cells (B, C)
were seeded onto Lab-Tek chamber slides and allowed to adhere overnight. Cells were fixed using methanol:acetone and stained for γH2AX (red).
Nuclear staining was achieved by DAPI (blue). Images were obtained by confocal microscopy. Level of γH2AX staining area was measured compared
to total nuclear area and plotted (D). Images represent 3 different mammosphere cultures.
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inhibitors led us to investigate the efficacy of their
combination with TKIs – Erlotinib and Gefitinib – at low
drug concentrations. Mammospheres were collected after
5–7 days in culture and total number of cells was evalu-
ated. Mammospheres were seeded in low-attachment
plates and treated with various combinations of the indi-
cated drugs, for up to 72 h. Mammosphere viability was
examined by the MTT viability assay. No significant ef-
fects were observed for up to 48 h in the combined treat-
ments, compared to the monotherapeutic effects of CPT
or etoposide (not shown). Note that neither Erlotinib nor
Gefitinib showed significant cytotoxicity as single agents
at the doses examined, for up to 72 h (not shown). How-
ever, both Erlotinib and Gefitinib were able to potentiate
the cytotoxic effect of topoisomerase inhibitors 72 hours
post-treatment, as depicted in Figure 11. Figure 11A dem-
onstrates that Gefitinib, at 5 μM, significantly potentiatedthe cytotoxic effect of CPT (p < 0.05). While CPT, at
0.1 μM, showed a cytotoxic effect of 22.9 ± 7.4%, the com-
bined treatment increased this effect to 53.9 ± 2.1%. At
0.02 μM CPT, Gefitinib was only able to increase the cyto-
toxic effect by 9.3%, from 18.8 ± 0.8% for CPT alone to
28.1 ± 2% in the combined treatment.
Similarly, Figure 11B demonstrates that Erlotinib, at
1 μM and 0.5 μM, significantly potentiated the cytotoxic
effect of etoposide (p < 0.05). While both Erlotinib and
etoposide, at either 5 μM or 1 μM, showed no cytotoxic
effect, the combined treatment revealed a striking increase
in cytotoxicity. At a concentration of 1 μM, Erlotinib
increased the cytotoxicity of etoposide to a level of
42.1 ± 16.5% and 46.4 ± 4.9% viability for 5 μM and
1 μM of etoposide, respectively. At a concentration of
0.5 μM, Erlotinib increased the cytotoxicity of etopo-
side to a level of 57.2 ± 10.8% and 34.1 ± 9.3% viability
for 5 μM and 1 μM of etoposide, respectively.
Figure 8 Effect of topoisomerase inhibitors on mammosphere-derived cells for 24 h. MCF7 cells were grown in non-adherent conditions.
After 7 days mammospheres were dissociated for single cells and plated in 96-well plates at a density of 5,000 cells/well, in the presence of 1%
serum. Cells were treated with various concentrations of etoposide (A), CPT (B) or TPT (C) for 24 h. Cell viability was examined by the neutral red
cytotoxicity assay and growth inhibition was calculated, compared to the control of each cell type. Results represent means ± SE of 3 experiments.
Statistical significance was determined by the student’s t-test analysis: *p < 0.05; **p < 0.01.
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In the past few decades there has been accumulating evi-
dence suggesting that tumors are generated by a subset of
rare cells, expressing stem/progenitor cell characteristics.
These cells, termed “cancer stem cells” (CSCs), have been
suggested to account for tumor growth, progression, me-
tastasis, and cancer relapse, as they display high tumori-
genicity in animal models and show increased resistance
to chemo- and radio-therapy [1,4,5,8,26].
Since topoisomerases are essential nuclear enzymes for
DNA transactions, we characterized their activity in mam-
mospheres derived from the MCF7 breast cancer cell line.This model has been widely studied for evaluation of CSC
biology, and here we utilized it as a model for the evalu-
ation of breast CSC response to topoisomerases inhibitors,
CPT and etoposide, and the combined treatments based
on these drugs with tyrosine kinase inhibitors (TKIs). For
this purpose, mammospheres were examined for topoi-
somerases activity in differentiating (10% FCS) and non-
differentiating (Growth Factors – GFs) conditions and
CD44+/CD24− breast stem cell markers were verified.
Indeed, mammospheres were enriched for the CD44+/CD24−
stem cell population, as established by immunostaining
and FACS analysis.
Figure 10 Mammosphere cell viability. Adherent MCF7 cells and mammospheres were plated as triplicates in 96-well plates, at a density of
5,000 cells/well and allowed to grow. Cell viability was determined every 24 hours by the MTT viability assay (black bars). Alternatively, adherent
MCF7 cells and mammospheres were cultured at a density of 106 cells\plate and allowed to grow. Cells were collected every 24 hours and
suspended with 1 ml of complete medium, after which 100 μl were transferred to 96-well plates, in triplicates. Cells were allowed to adhere overnight
and cell viability was evaluated by the Neutral Red viability assay (white bars). Results represent means ± SE of at least 3 experiments. Statistical significance
was determined by the student’s t-test analysis, compared to the adherent control.
Figure 9 Cytotoxic effect of CPT and etoposide on intact mammospheres. Mammospheres were collected after 5–7 days in culture and
total number of cells was evaluated. Adherent MCF7 cells and intact mammospheres were seeded in 96-well plates at a density of 5,000 cells/well.
The parental MCF7 cells were allowed to adhere over night, after which cells were treated with various doses of CPT (A, B) or etoposide (C, D)
for 24 (A, C) or 48 hours (B, D). Cell viability was examined by the MTT viability assay. Results for CPT represent means ± SE of 2 experiments.
Results for etoposide represent means ± SE of 3 experiments. Statistical significance was determined by the student’s t-test analysis: *p < 0.05.
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Figure 11 Cytotoxic effect of a combined treatment with CPT and Gefitinib or etoposide and Erlotinib on intact mammospheres.
Mammospheres were collected after 5–7 days in culture and total number of cells was evaluated. Intact mammospheres were seeded in low-attachment
96-well plates at a density of 5,000 cells/well, after which cells were treated with (A) the combination of CPT (0.1 μM or 0.02 μM) and Gefitinib
(5 μM or 1 μM), or (B) the combination of etoposide (5 μM or 1 μM) and Erlotinib (1 μM or 0.5 μM) for 72 hours. Cell viability was examined by
the MTT viability assay. Results represent means ± SE of 2 experiments. Statistical significance was determined by the student’s t-test analysis:
*p < 0.05.
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hibited similar behavior throughout this study, they will
not be distinguished in this section.
Examination of topoisomerases activity reveals that, in
comparison with the parental adherent MCF7 cell line,
mammospheres exhibit reduced topo I activity. Conversely,
topo II activity is increased in mammospheres. When we
examined topoisomerases protein levels we did not observe
changes relative to the loading controls, β-actin and lamin
B; however, an overall reduction was observed in all four
proteins. It has been previously shown that changes in cell
morphology and culture adherence status lead to alteredexpression of β-actin [27]. Embryonic chicken fibroblasts,
treated with Phorbol-12-myristate-13-acetate (PMA),
were found to create foci of densely packed cells that
stopped adhering to the plates and had reduced levels of
β-actin mRNA and protein. In contrast, floating chon-
drocytes treated with PMA adhered to the culture dish
and displayed increased β-actin mRNA and protein
levels [27]. Since the process of CSC isolation involves
cell growth in floating conditions and results in the forma-
tion of seemingly packed spheres, it is possible that this
morphology leads to the observed reduction in β-actin
protein levels.
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duced in mammospheres. It has been reported that
while lamin B is not needed for proper self-renewal and
pluripotency of embryonic stem cells, lamin B interac-
tions with chromatin are increased after differentiation,
thereby suppressing gene transcription, showing their
importance in lineage determination [28]. Lamin B has
also been shown to be involved in the formation of nu-
clear skeletal support [29], which might also be modified
due to structural changes during mammosphere forma-
tion, similarly to β-actin. Lamin B has been shown to be
involved in replication, as it localizes with the replication
factor proliferating cell nuclear antigen (PCNA) in the
replication machinery during late S phase [29]. Since
mammospheres exhibit a low cycling phenotype, the re-
duced level of lamin B might also be a mechanism of the
mammospheres, as shown by the cell viability assays.
Although an overall reduction was observed in the
level of nuclear proteins, at least for the indicated pep-
tides, the relative level of topo I enzyme protein was not
changed in mammospheres, compared with the adher-
ent MCF7 cells. When we examined the sensitivity of
the enzyme to topo I inhibitor CPT, an expected resist-
ance was observed. This prompted us to investigate a
possibility that topo I protein might be altered in mammo-
spheres, translationally (i.e., alternative splicing or folding)
or post-translationally. To examine this possibility, topo I
activity levels of the adherent-derived and mammosphere-
derived enzymes were normalized in vitro. CPT sensitivity
was examined and revealed a similar inhibition level in
both cell types (data not shown), suggesting that it is not a
translational, but a posttranslational modification.
Topo I has been shown to be regulated by poly-ADP-
ribose polymerase 1 (PARP-1). While poly-ADP-ribosylation
by PARP-1 reduces the activity of topo I, a direct interaction
between the two enzyme proteins leads to topo I activa-
tion [24,30-32]. Since topo I activity is reduced in mam-
mospheres, PARP-1 poly-ADP-ribosylation activity was
inhibited in mammospheres by 3-aminobenzamide (3AB).
Indeed, topo I activity was restored to a similar level as
that of adherent MCF7 cells treated with 3AB, indicating
that topo I is regulated, at least in part, by PARP-1.
PARP-1 is a ubiquitous nuclear enzyme that is activated
in response to DNA damage [33]. The observation that
topo I is regulated by PARP-1 in mammospheres, lead us
to investigate the possibility that the reduction in topo I
activity might result from DNA damage-induced PARP-1
activation. For this purpose, we examined the formation
of phosphorylated histone 2AX (γH2AX) foci in the nu-
cleus, which are a hallmark of DNA breaks [25]. Indeed,
mammospheres exhibit increased levels of γH2AX, com-
pared to the adherent MCF7 cells.
Although increased γH2AX can be regarded as DNA
damage, it has been shown that γH2AX induction canbe a result of chromatin remodeling, a process that has
been characterized during stem cell renewal and differ-
entiation, without activation of DNA damage response
[25]. Indeed, PARP-1 is also involved in the process of
chromatin remodeling [34]. Furthermore, topo I has been
shown to be reduced in differentiated cells; however, it has
also been shown to be lower in non-proliferating cells,
compared to log-phase proliferating cells [35], which
might point to several processes that regulate topo I activ-
ity within the sphere.
These questions led us to investigate whether the reduc-
tion in topo I activity is a global characteristic of cancer
stem cells. CSCs were isolated as spheres from various cell
types, including mouse mammary 4 T1-Luc tumor cells
that express zsGreen fluorescent protein under the Oct3/4
promoter, and the PC3 human prostate cancer cells.
Mammospheres derived from 4 T1-Luc-Oct3/4pG cells
were examined for Oct3/4 expression, as an indicator of
stem properties, since Oct 3/4 transcription factor is a
known stem cell marker, which was shown to be critical
for maintaining stem cell characteristics [36]. PC3-derived
prostaspheres were examined for the expression of stem
cell marker CD133.
After establishment of stem-like properties, 4 T1-
Luc-Oct3/4pG- and PC3-derived spheres were exam-
ined for topo I activity. Similar results were obtained
for both cell types, as topo I activity was reduced in
comparison to the parental adherent cells, indicating a
global tumorsphere property. It has been shown that
Oct3/4-expressing cancer stem-like cells (express GFP
under Oct3/4 promoter), isolated from breast cancer cell
lines, and CD49f+ primary cancer cells exhibit higher topo
I activity and protein level, and display increased sensitiv-
ity to topo I inhibitors [37]. In contrast CD44+ stem-like
cells, isolated from colorectal cancer cell line, displayed re-
duced topo I activity and insensitivity of the enzyme to
camptothecin, compared to the CD44− subpopulation
[38]. In both studies tumor spheres were not isolated as
described in this manuscript. Mammospheres can be gen-
erated by single cells, as we also observed in both FCS and
GFs-supplemented media (not shown), and yet display a
heterogenic progenitor composition [22]. Although sphere
assays are being extensively used to evaluate stem cell ac-
tivity in normal tissue and CSCs, in the majority of these
cultures there is no definitive information as to which cells
are being propagated. The characteristics of spheres and
their relationship with their stem cells have been unclear,
causing over-interpretation of results in many cases. This
is largely because extensive self-renewal has been difficult
to define in the context of a sphere assay [8]. It is possible
then, that along with self-renewal of CSCs, differentiation
processes can take place. Indeed, mammospheres only ex-
hibit approximately 15–20% of the CD44+/CD24− stem
cell population (as observed by FACS analysis); thus the
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under these conditions. All together these observations
suggest that topo I activity and expression in CSCs might
be influenced by the sphere structure and composition.
Since mammospheres exhibit a relatively low cycling
rate and no relative changes in the level of topo II protein,
chromatin remodeling during self-renewal and differenti-
ation processes within the sphere might also explain the
increased topo II activity, as the enzyme is necessary for
this process. An alternative explanation for topo II in-
creased activity could be a compensation mechanism,
caused by the reduced topo I activity. Although topo II
has been mostly shown to compensate for topo I reduc-
tion after treatment with CPT, as observed by increased
levels of the topo II protein [39], the reduction in topo I
activity by a posttranslational modification, rather than
protein downregulation, might similarly lead to increased
topo II activity. Indeed, it has been shown that topo II
compensates for topo I deficiency in a stable siRNA
model. Moreover, this compensation correlated with in-
creased γH2AX foci, chromosomal rearrangement, and
chromatin remodeling activities [40].
Since topo I showed reduced activity and consequently
increased resistance to CPT in vitro, we examined the
sensitivity of mammosphere-derived topo II to etopo-
side. As expected, topo II showed increased sensitivity to
etoposide.
The response of topoisomerases to their corresponding
inhibitors, in correlation with their activity in vitro,
prompted us to examine the sensitivity of mammospheres
to CPT and etoposide. First we examined the sensitivity of
mammosphere-derived cells to these drugs. Again, cells
expectedly displayed an increased resistance to CPT, cor-
related with the reduced topo I activity. In addition,
mammosphere-derived cells exhibit increased sensitivity
to etoposide, which correlates with the increased topo II
activity. These results are compatible with a previous ob-
servation in an epithelial-mesenchymal transition (EMT)
model of breast CSC, in which anti-cancer agents were
screened by their CSC-specific toxicity, revealing in-
creased cytotoxicity for etoposide and reduced cytotoxicity
for CPT [41].
Next, we examined the sensitivity of intact mammo-
spheres to topoisomerases inhibitors. Surprisingly, while
mammospheres exhibit increased resistance to CPT, as
expected, this effect was also observed for etoposide. It
has been demonstrated that CSCs express high levels of
ABC transporters, as this characteristic enables their iden-
tification by the “dye efflux” assay. It is known that etopo-
side is a substrate for MDR protein [42]. The contradicting
results shown for etoposide in mammosphere-derived cells
and intact mammospheres could be explained by the fact
that the Neutral red cytotoxicity assay performed with
mammosphere-derived cells requires cells to adhere to theculture plate. The heterogeneous composition of mammo-
sphere cells might indicate that not all cells within the
sphere express MDR transporters. It has been shown that
mammospheres of a tamoxifen-resistant MCF7 cell line
exhibits increased breast cancer resistance protein (BCRP)
levels in response to tamoxifen treatment. The expression
of BCRP was mostly expressed in the outer cells of the
mammosphere [43]. It is possible that the cellular interac-
tions and compartments within the sphere might allow for
proper protection of the inner mass of the sphere after ex-
posure to anti-cancer drugs, thus enabling efficient ATP
management. This characteristic could be lost after sphere
dissociation and changes in growth conditions. It is notable
that CPT is a poor substrate for MDR [44]; thus the re-
duced sensitivity in mammospheres is mostly due to the
reduction of topo I activity.
When we examined the cytotoxicity of the combined
treatments we observed that Gefitinib increased the anti-
cancer effect of CPT in mammospheres; however Erlotinib
failed to show a significant beneficial effect in the com-
bined treatment, compared to each drug administered
alone, in a preliminary examination. While mammospheres
were resistant to etoposide, the addition of Erlotinib dra-
matically increased its cytotoxic effect. Combination with
Gefitinib, however, showed no significant beneficial effect
in the combined treatment with etoposide, compared to
each drug administered alone in a preliminary examination.
Several studies have shown that both Gefitinib and
Erlotinib can modulate the activity of ABC transporters
and invert resistance of cancer cells [45-48]. While the
ability of Erlotinib to increase the anti-tumor effect of
etoposide in mammospheres could be attributed to its
potential to inhibit MDR proteins, it could also exert its
anti-EGFR and anti-topoisomerase activity [17]. However,
since CPT is a poor substrate for MDR transporters, Gefi-
tinib was able to increase its cytotoxic effect, albeit to a
lesser extent than that observed with the combination of
etoposide and Erlotinib, probably due to the low activity
of the enzyme. Erlotinib, on the other hand, was not able
to potentiate CPT’s effect, which might strengthen the
notion that its activity modulates MDR. The different
abilities of Erlotinib and Gefitinib should be further
established, as they might require dose adjustments or
different treatment durations.
The growing evidence pointing to the existence of
tumor-initiating stem cells and their role in tumor resist-
ance, progression, metastasis, and cancer relapse after
anti-cancer treatments, underlines the great importance
in understanding their biological activity and subsequent
ability to respond to specific treatment protocols. Al-
though we show here that the initial stages of tumor
growth, represented by the formation of tumorspheres,
might be involved in extreme changes of the activity and
expression of essential enzymes due to complex cellular
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as the mammosphere system raises more questions than
answers.
Conclusion
Understanding the process of early tumor development
could be of great value, as cancer, if not cured, could be-
come a controlled illness, reducing mortality rates and
increasing life expectancy and quality for patients. In-
deed, in this study we show that the understanding of
the biological activity of essential cellular enzymes, such
as topoisomerases, at early cancer development stages,
may suggest treatment strategies for the development of
potent, more effective treatment protocols and that the
combination of TKIs and topoisomerases inhibitors could
be effective against breast cancer.
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